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Epigenetic processes, including DNA methylation (DNAm), are among the mechanisms
allowing integration of genetic and environmental factors to shape cellular function. While
many studies have investigated either environmental or genetic contributions to DNAm, few
have assessed their integrated effects. Here we examine the relative contributions of prenatal
environmental factors and genotype on DNA methylation in neonatal blood at variably
methylated regions (VMRs) in 4 independent cohorts (overall n = 2365). We use Akaike’s
information criterion to test which factors best explain variability of methylation in the
cohort-speciﬁc VMRs: several prenatal environmental factors (E), genotypes in cis (G), or
their additive (G + E) or interaction (GxE) effects. Genetic and environmental factors in
combination best explain DNAm at the majority of VMRs. The CpGs best explained by either
G, G + E or GxE are functionally distinct. The enrichment of genetic variants from GxE models
in GWAS for complex disorders supports their importance for disease risk.

Correspondence and requests for materials should be addressed to E.B.B. (email: binder@psych.mpg.de). #A full list of authors and their afﬁliations appears at
the end of the paper.
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oetal or prenatal programming describes the process by
which environmental events during pregnancy inﬂuence the
development of the embryo with on-going implications for
future health and disease. Several studies have shown that the in
utero environment is associated with disease risk, including
coronary heart disease1,2, type 2 diabetes3, childhood obesity4,5 as
well as psychiatric problems6 and disorders7–9.
Environmental effects on the epigenome, for example, via DNA
methylation, could lead to sustained changes in gene transcription and thus provide a molecular mechanism for the enduring
inﬂuences of the early environment on later health10. Smoking
during pregnancy inﬂuences widespread and highly reproducible
differences in DNA methylation at birth11. Less dramatic effects
have been reported for maternal body mass index (BMI)12, preeclampsia and gestational diabetes13,14. Possible epigenetic
changes as a consequence of prenatal stress are less well established15. Some of these early differences in DNA methylation
persist, although attenuated, through childhood11,16 and might be
related to later symptoms and indicators of disease risk, including
BMI during childhood17,18 or substance use in adolescence19.
These data emphasise the potential importance of the prenatal
environment for the establishment of inter-individual variation in
the methylome as a predictor or even mediator of disease risk
trajectories.
In addition to the environment, the genome plays an important
role in the regulation of DNA methylation. To this end, the impact
of genetic variation, especially of single nucleotide polymorphisms
(SNPs) on DNA methylation in different tissues, has resulted in
the discovery of a large number of methylation quantitative trait
loci (meQTLs, i.e., SNPs signiﬁcantly associated with DNA
methylation status20). These variants are primarily in cis, i.e.,
at most 1 million base pairs away from the DNA methylation
site20–22 and often co-occur with expression QTLs or other regulatory QTLs23–25. The association of meQTLs with DNA
methylation is relatively stable throughout the life course21. In
addition, SNPs within meQTLs are strongly enriched for genetic
variants associated with common disease in large genome-wide
association studies (GWAS) such as BMI, inﬂammatory bowel
disease, type 2 diabetes or major depressive disorder21,23,24,26.
Environmental and genetic factors may act in an additive or
multiplicative manner to shape the epigenome to modulate
phenotype presentation and disease risk27. However, very few
studies have so far investigated the joint effects of environment
and genotype on DNA methylation, especially in a genome-wide
context. Klengel et al.28, for instance, reported an interaction of
the FK506 binding protein 5 gene (FKBP5) SNP genotype and
childhood trauma on FKBP5 methylation levels in peripheral
blood cells, with trauma associated changes only observed in
carriers of the rare allele. The most comprehensive study of
integrated genetic and environmental contributions to DNA
methylation so far was performed by Teh et al.29. This study
examined variably methylated regions (VMRs), deﬁned as regions
of consecutive CpG-sites showing the highest variability across all
methylation sites assessed on the Illumina Inﬁnium HumanMethylation450 BeadChip array. In a study of 237 neonate
methylomes derived from umbilical cord tissue, the authors
explored the proportions of the inﬂuence of genotype vs. prenatal
environmental factors such as maternal BMI, maternal glucose
tolerance and maternal smoking on DNA methylation at VMRs.
They found that 75% of the VMRs were best explained by the
interaction between genotype and environmental factors (GxE)
whereas 25% were best explained by SNP genotype and none by
environmental factors alone. Collectively, these studies highlight
the importance of investigating the combination of environmental and genetic contributions to DNA methylation and not
only their individual contribution.
2

The main objective of the present study is to extend our
knowledge of combined effects of prenatal environment and
genetic factors on DNA methylation at VMRs. Speciﬁcally, this is
addressed by: (1) assessing the stability of the best explanatory
factors across different cohorts and whether this extends to all
environmental factors, (2) dissecting differences between additive
and interactive effects of gene and environment not explored in
Teh et al., (3) testing whether VMRs inﬂuenced by genetic and/or
environmental factors might have a different predicted impact on
gene regulation and (4) evaluating the relevance of genetic variants that interact with the environment to shape the methylome
for their contribution to genetic disease risk.
Our results show that across cohorts genetic variants in combination with prenatal environment are the best predictors of
variance in DNA methylation. We observe functional differences
of both the genetic variants and the methylation sites best
explained by genetic or additive and interactive effects of genes
and environment. Finally, the enrichment of genetic variants
within additive as well as interactive models in GWAS for complex disorders supports the importance of these environmentally
modiﬁed methylation quantitative trait loci for disease risk.
Results
Cohorts and analysis plan. We investigated the inﬂuence of the
prenatal environment and genotype on VMRs in the DNA of
2365 newborns within 4 different cohorts: Prediction and Prevention of Pre-eclampsia and Intrauterine Growth Restrictions
(PREDO, cordblood)30, the UCI cohort (refs. 31–33, heel prick),
the Drakenstein Child Health Study (DCHS, cordblood)34,35 and
the Norwegian Mother and Child Cohort Study (MoBa, cordblood36). A description of the workﬂow of this manuscript is
given in Fig. 1 and the details for each of the cohorts are given in
Table 1.
We analysed 963 cord blood samples from the PREDO cohort
with available genome-wide DNA methylation and genotype
data. Of these samples, 817 had data on the Illumina 450k array
(PREDO I) and 146 on the Illumina EPIC array (PREDO II). The
main analyses are reported for PREDO I, and replication and
extension of the results is shown for PREDO II as well as for three
independent cohorts including 121 heel prick samples (UCI
cohort, EPIC array) as well as 258 (DCHS, 450 K and EPIC array)
and 1023 cord blood samples (MoBa, 450 K array). We tested 10
different prenatal environmental factors covering a broad
spectrum of prenatal phenotypes (see Table 1) (referred to as
E), as well as cis SNP genotype (referred to as G), i.e., SNPs
located in at most 1MB distance to the speciﬁc CpG, additive
effects of cis SNP genotype and prenatal environment (G + E)
and cis SNP×environment interactions (GxE) for association with
DNA methylation levels (see Fig. 1). We then assessed for each
VMR independently which model described the variance of
DNAm best using Akaike’s information criterion (AIC)37. In all
models, we corrected for child’s gender, ethnicity (using MDScomponents), gestational age as well as estimated cell proportions
to account for cellular heterogeneity.
Variably methylated regions. We ﬁrst identiﬁed candidate
VMRs, deﬁned as regions of CpG-sites showing the highest
variability across all methylation sites. In PREDO I, we identiﬁed
10,452 variable CpGs that clustered into 3982 VMRs (see Supplementary Data 1). Most VMRs (n = 2683) include 2 CpGs. As
detailed in Supplementary Note 1, the distribution of methylation
levels of CpGs within these VMRs is unimodal, (see Supplementary Fig. 1A), VMRs are enriched in speciﬁc functional
regions of the genome, correlate with differences in gene
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Determine variably methylated regions (VMRs): CpG-sites with MAD-score >
ninetieth percentile and at least 2 consecutive CpGs with at most 1 kb distance

tagCpG: choose CpG-site with highest MADscore within each VMR as representative
For each tagCpG

For all DeepSEA SNPs in 1 MB cis
distance to tagCpGs

For ten prenatal E

Model G:
tagCpG ~ cis DeepSEA variants

Model E:
tagCpG ~ environmental
phenotypes

Keep model with lowest AIC
across all G models

Keep model with lowest AIC across
all E models

For ten prenatal E x DeepSEA SNPs in 1 MB cis of tag CpG
Model G+E:
tagCpG ~ cis DeepSEA
variants + environmental
phenotypes

Model GxE:
tagCpG ~ cis DeepSEA
variants x environmental
phenotypes

Keep model with lowest AIC
across all G+E models

Keep model with lowest AIC
across all GxE models

Determine model with lowest AIC across E, G,
G+E and GxE models as best model for each
tagCpG

Functional annotation of tagCpGs/DeepSEA
variants stratified by best model E, G, G+E, GxE

Replication of partition in best model E, G, G+E
and GxE in independent cohorts

Fig. 1 Flow diagram of VMR analysis

expression, and overlap with sites associated with speciﬁc prenatal
environmental factors.
To examine the factors that best explain the variance in
methylation in these functionally relevant sites, we chose the
CpG-site with the highest MAD score as representative of the
VMR. These CpGs are named tagCpGs. The correlation between
methylation levels of tagCpG and average methylation of the
respective VMR was high (mean r = 0.85, sd r = 0.08), suggesting
that the tag CpGs are valid representatives of their VMRs.
Furthermore, tagCpGs are mainly uncorrelated with each other
(mean r = 0.03, sd = 0.12).
Which models explain methylation of tagCpGs best? We next
compared the ﬁt of four models for each of the 3,982 tagCpGs
(see Fig. 1): best SNP (G model), best environment (E model),
SNP+ environment (G + E model) and SNP× environment (GxE
model). Association results for each model are listed in Supplementary Data 2–5. For each tagCpG, the model with the lowest
AIC was chosen as the best model (see Methods section). In total,
40.6% of tagCpGs were best explained by GxE (n = 1616), followed by G (30%, n = 1, 194) and G + E (29%, n = 1171)
(Fig. 2a). E explained most variance in one tagCpG. All tag CpGs
and the respective SNPs and environments from the best model
are listed in Supplementary Data 6–8 and Supplementary Table 1.
With regard to environmental factors, 27.0% of tagCpGs best
explained by the G + E model were associated with environmental factors related with stress or, in particular, glucocorticoids
(i.e., maternal betamethasone treatment), 40.8% with general
maternal factors (mostly maternal age) and 32.20 % with factors
related to metabolism (pre-pregnancy BMI, hypertension,

gestational diabetes). For best model GxE tagCpGs, the proportions of environmental factors were similar with 22.2, 44.1 and
33.7%, respectively (see Fig. 2b).
We next looked into the delta AIC, i.e., the difference between
the AIC of the best model to the AIC of the next best model (see
Supplementary Note 2). GxE models appear to be winning by a
signiﬁcantly larger AIC margin over the next best model, when
compared to the other types of winning models (see Fig. 2c).
DeepSEA prediction of SNP function. We were next interested
in understanding the functionality of both the VMRs as well as
the associated SNPs in the G, GxE and G + E models. For this we
restricted the analyses only to potentially functional relevant
SNPs using DeepSEA38 and not all linkage disequilibrium (LD)pruned SNPs as described above. DeepSEA, a deep neural network pretrained with DNase-seq and ChIP-seq data from the
ENCODE39 project, predicts the presence of histone marks,
DNase hypersensitive regions (DHS) or TF binding for a given 1
kb sequence. The likelihood that a speciﬁc genetic variant inﬂuences regulatory chromatin features is estimated by comparing
predicted probabilities of two sequences where the bases at the
central position are the reference and alternative alleles of a given
variant. We reran the four models now restricting the cis-SNPs to
those 36,241 predicted DeepSEA variants that were available in
our imputed, quality-controlled genotype dataset.
Top results for models including G, GxE and G + E are
depicted in Supplementary Data 9–12.
Results were comparable to what we observed before: 1195
(30.09%) of tagCpGs presented with best model G, 1193 CpGs
(30.04%) with best model G + E, 1510 CpGs (38.02%) with best
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Table 1 Overview of investigated cohorts
Cohort
Sample size
Methylation array
Methylation data
processing
SNP genotyping

Infant gender male
Maternal age
mean (sd)
Partity mean (sd)
Caesarian section
Pre-pregnancy BMI
mean (sd)
Maternal smoking yes
Gestational
diabetes yes
Hypertension yes
Betamethasone
treatment yes
Anxiety score
mean (sd)
Depression score
mean (sd)

PREDO I
817
Illumina 450 K
Funnorm
and Combat
Illumina Human
Omni
Express Exome
433 (53.0%)
33.28 (5.79)

PREDO II
146
Illumina EPIC
Funnorm
and Combat
Illumina Human
Omni
Express Exome
75 (51.4%)
32.25 (4.92)

DCHS I
107
Illumina 450 K
SWAN
and Combat
Illumina
PsychArray

DCHS II
151
Illumina EPIC
BMIQ
and Combat
Illumina GSA

UCI
121
Illumina EPIC
Funnorm
and Combat
Illumina Human
Omni Express

MoBa
1023
Illumina 450 K
BMIQ and Combat

63 (58.8%)
26.27 (5.87)

83 (55.0%)
27.42 (5.93)

65 (53.7%)
28.47 (4.91)

478 (46.7%)
29.92 (4.32)

1.05 (1.02)
169 (20.7%)
27.42 (6.40)

0.87 (1.03)
36 (24.7%)
25.37 (5.79)

0.98 (1.12)
19 (17.6%)
Not available

1.09 (1.07)
35 (23.2%)
Not available

1.11 (1.15)
37 (30.6%)
27.90 (6.44)

0.83 (0.88)
228 (22.3%)
24.05 (4.19)

Exclusion criterion
183 (22.4%)

Exclusion criterion
19 (13.0%)

148 (14.4%)
15 (1.5%)

31 (21.2%)
2 (1.5%)

4.94 (9.43)a
No cases
available
2 (1.3%)
Not available

10 (8.2%)
9 (7.4%)

275 (33.7%)
35 (4.3%)

7.40 (10.52)a
No cases
available
2 (0.19%)
Not available

50 (4.9%)
Not available

33.93 (7.90)b

34.43 (8.38)b

5.70 (4.15)c

5.32 (3.91)c

7 (5.8%)
No cases
available
1.67 (0.41)d

4.79 (1.36)e

11.34 (6.47)f

11.53 (6.98)f

17.64 (12.10)g

12.52 (11.55)g

0.68 (0.41)h

5.24 (1.57)e

Illumina
HumanExome Core

a Based on ASSIST Tobacco Score
b STAI sum scores
c SRQ-20
d STAI average scores
e Based on Hopkins Symptom Checklist
f CESD sum scores
g BDI-II
h CESD average score

model GxE and 74 CpGs (1.86%) with best model E (Fig. 3a) and
also showed similar differences in delta-AIC and proportions of E
categories (see Supplementary Note 3). Only 10 tagCpGs did not
present with any DeepSEA variant within 1MB distance in cis and
were therefore not further considered. All respective CpGenvironment-DeepSea SNP combinations are depicted in Supplementary Data 13–16.
The distribution of best models was not inﬂuenced by the
degree of variability of DNA methylation, but was comparable
across the whole range of DNA methylation variation (see
Supplementary Note 4 and Supplementary Fig. 2). A slight
enrichment for G + E models was observed in longer VMRs with
at least 3 CpGs (p = 9.00 × 10−06, OR = 1.39, Fisher-test, see
Supplementary Fig. 3).
In conclusion, also when we focus on potentially functionally
relevant SNPs, it is the combination of genotype and environment
which best explains VMRs.
We observed that, as expected, different types of exposures or
maternal factors have different relative impact on DNA
methylation (see Supplementary Note 5). However, even for
those exposures with the highest fraction of VMRs best explained
by E alone, combined models of G + E and GxE remain the best
models in even higher fractions of VMRs (see Supplementary
Fig. 4B).
Functional annotation of different best models. Focusing on
combinations between tagCpGs, environmental factors and
DeepSEA variants, we found functional differences for both the
SNPs as well as the tagCpGs (see Supplementary Note 6) within
the different models. Overall, 895 DeepSEA variants were
uniquely involved in best G models, 905 were uniquely in best
4

G + E models and 1162 uniquely in best GxE models. As a
DeepSEA variant can be in multiple 1 MB-cis windows around
the tagCpGs, several DeepSEA variants were involved in multiple
best models: 138 DeepSEA variants overlapped between G and
GxE, 118 between G and G + E and 147 between GxE and G + E
VMRs. We observed no signiﬁcant differences with regard to
gene-centric location for DeepSEA variants involved only in G
models, only in G + E models or in multiple models. However,
DeepSEA variants involved only in GxE models were signiﬁcantly
depleted for promoter locations (p = 3.92 × 10−02, OR = 0.79,
Fisher-test, see Supplementary Fig. 5A).
Although no signiﬁcant differences were present, DeepSEA
SNPs involved in the G and G + E model were located in
closer proximity to the speciﬁc CpG (model G: mean absolute
distance = 256.8 kb, sd = 291.2 kb, model G + E: mean absolute
distance = 244.8 kb, sd = 284.0 kb, Supplementary Fig. 5B)
whereas DeepSEA SNPs involved in GxE models (mean absolute
distance = 352.6 kb, sd = 305.3 kb) showed broader peaks around
the CpGs.
With regards to histone marks, DeepSEA variants in general
were enriched across multiple histone marks indicative of active
transcriptional regulation (Fig. 4c). DeepSEA variants involved in
best model G + E showed further enrichment for strong
transcription (p = 7.19 × 10−03, OR = 1.34, Fisher-test) as well
as depletion for quiescent loci (p = 7.17 × 10−03, OR = 0.78,
Fisher-test). In contrast, GxE DeepSEA variants were signiﬁcantly
enriched in these regions (p = 2.62 × 10−02, OR = 1.22, Fishertest, Fig. 4d).
Taken together, these analyses indicate that both the genetic
variants and the VMRs in the different best models (G, GxE and
G + E) preferentially annotate to functionally distinct genomics
regions.
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a

b
1.00

1.00

24.81%

29.98%

30.56%

0.75

0.75

E
29.41%
G

0.50

8.47%

Type

9.05%

Type

G+E
GxE

Percentage of CpGs

Percentage of CpGs

21.59%

9.67%
9.30%

6.90%
6.29%

0.50
24.64%

28.41%
30.64%

0.25
0.25

40.58%

12.66%

12.65%

11.82%

10.59%

7.47%

8.54%

6.62%

G+E

GxE

tagCpGs

Anxiety score
Betamethasone intake
Delivery mode
Depression score
Gestational diabetes
Maternal age
Maternal hypertension
Maternal pre–pregnancy BMI
Ogtt
Parity

10.67%

0.00

7.96%

0.00
PREDOI pruned genotypes

c
15

10
p = 2.22×10–96

5
p = 4.78×10–80

0
E

G

G+E

GxE

Fig. 2 VMR analysis in pruned PREDO I dataset. a Percentage of models (G, E, GxE or G + E) with the lowest AIC explaining variable DNA methylation
using the PREDO I dataset with pruned SNPs. b Distribution of the different types of prenatal environment included in the E model with the lowest AIC
(right), in the combinations yielding the best model GxE (middle), or the best model G + E models (left). To increase readability all counts <3% have been
omitted. c DeltaAIC, i.e, the difference in AIC, between best model and next best model, stratiﬁed by the best model. Y-axis denotes the delta AIC and the
X-axis the different models. The median is depicted by a black line, the rectangle spans the ﬁrst quartile to the third quartile, whiskers above and below the
box show the location of minimum and maximum beta-values. P-values are based on Wilcoxon-tests

Replication of best models in independent cohorts. To assess
whether the relative distribution of the best models for VMRs and
DeepSEA variants was stable across different samples, we assessed
the relative distribution of these models in 3 additional samples
(DCHS I and DCHS II, UCI and PREDOII) with VMR data both
from the Illumina 450 K as well as the IlluminaHumanEPIC
arrays. Information on these cohorts is summarised in Table 1
and the number of VMRs, the distribution of VMR methylation
levels, VMR length and speciﬁc SNP information are given in
Supplementary Note 7 and Supplementary Fig. 6.
While major maternal factors overlapped among the cohorts such as maternal age, delivery method, parity and depression
during pregnancy - there were also differences, as the nonPREDO cohorts did not include betamethasone treatment but
additionally included maternal smoking (see Table 1). Despites
these differences and differences in the total number of VMRs,
the overall pattern remained stable: in all 4 analyses, DCHS I,

DCHS II, UCI and PREDO II, we replicated that E alone models
almost never explained most of the variances, while G alone
models explained the most variance in up to 15% of the VMRs;
G + E in up to 32%; and GxE models in up to 60% (see Fig. 5 and
Table 2).
The importance of including G for a best model ﬁt could also
be observed for maternal smoking, described as one of the most
highly replicated factors shaping the newborns’ methylome11 and
present in the replication but not the discovery cohort PREDO I.
These analyses are detailed in Supplementary Note 8.
We were also able to replicate our ﬁnding showing that GxE
VMRs were enriched for OpenSea positions with a trend on the
450 K array (DCHS I, OR = 1.11, p = 5.03 × 10−02, Fisher-test)
and signiﬁcantly for the EPIC array data (PREDOII: p = 2.96 ×
10−06, OR = 1.29, UCI: p = 3.79 × 10−02, OR = 1.09, DCHSII:
p = 2.91 × 10−04, OR = 1.16, Fisher-tests). For all additional
cohorts, the delta AIC for best model GxE to the next best
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40.08%
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5.28%

5.50%
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0.00

36.49%

32.97%
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31.55%

G

G+E

GxE
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PREDO I DeepSEA SNPs

c
0.00
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8.11%

5.61%
3.01%

Percentage of CpGs

75

27.03%

31.60%

6.37%

7.28%

3.52%

3.78%

30.93%

29.47%

28.2%

5.02%
5.28%

50

6.42%

6.44%

29.08%

Type

5.45%

18.92%
21.34%
22.04%

18.34%

E

3.28%

19.52%

1st Exon
1st Intron
3′ UTR
5′ UTR
Distal intergenic
Downstream (<=3 kb)
Other exon
Other intron
Promoter

25
35.13%

31.72%
27%

30.27%

31.51%

GxE

VMRs

0
E

G

G+E

Fig. 3 VMR analysis in DeepSEA annotated SNPs in PREDO I dataset. a Percentage of models (G, E, GxE or G + E) with the lowest AIC explaining variable
DNA methylation using the PREDO I dataset with DeepSEA annotated SNPs. b Distribution of the locations of all VMRs and tagVMRs with best model E, G,
G + E and GxE on the 450k array using only DeepSEA variants in relationship to CpG-Islands based on the Illumina 450 K annotation. c Distribution of
gene-centric locations of all VMRs and tagVMRs with best model E, G, G + E and GxE on the 450k array using only DeepSEA variants

model was also signiﬁcantly higher as compared to CpGs with G,
E or G + E as the best model.
Overall, 387 tag CpGs overlapped between PREDO I, PREDO
II, DCHS I and DCHS II (see Supplementary Fig. 7), which
allowed us to test the consistency of the best models for speciﬁc
VMRs across the different cohorts. Over 70% of the overlapping
tagCPGs showed consistent best models in at least 3 cohorts (see
Fig. 6) with GxE being the most consistent model (for over 60%
of consistent models, see Supplementary Fig. 8). Focusing only on
EPIC data (PREDO II, DCHSII and UCI), we identiﬁed more,
namely 2091, tag CpGs that overlap across the three cohorts and
here 86% show a consistent best model in at least two of the three
cohorts, despite differences in study design, prenatal phenotypes
and ethnicity.
Thus, the additional cohorts not only showed a consistent
replication of the proportion of the models best explaining
variance of VMRs but also consistency of the best model for
speciﬁc VMRs. Within this context, we observed the GxE models
were the most consistent models across the cohorts (see
Supplementary Fig. 8), with 85% of the CpGs with consistent
6

models across 5 cohorts having GxE as the best model.
Furthermore, we could validate speciﬁc GxE combinations
between PREDO I and MoBa as shown as in the Supplementary
Note 9, in Supplementary Data 17 and 18 and in Supplementary
Fig. 9.
Disease relevance. Finally, we tested whether functional DeepSEA SNPs involved in only G, only GxE and only G + E models
in PREDO I for their enrichment in GWAS hits. We used all
functional SNPs and their LD proxies (deﬁned as r2 of at least 0.8
in the PREDO cohort and in maximal distance of 1MB to the
target SNP) and performed enrichment analysis with the overlap
of nominal signiﬁcant GWAS hits. We selected for a broad
spectrum of GWAS, including GWAS for complex disorders for
which differences in prenatal environment are established as risk
factors, but also including GWAS on other complex diseases. For
psychiatric disorders, we used summary statistics of the Psychiatric Genomics Consortium (PGC) including association studies for autism40, attention-deﬁcit-hyperactivity disorder41,
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Fig. 4 Functional annotation of VMR-mapping in DeepSEA annotated SNPs in PREDO I dataset. a Histone mark enrichment for all VMRs. The Y-axis
denotes the fold enrichment/depletion as compared to no-VMRs. Blue bars indicate signiﬁcant enrichment/depletion, grey bars non-signiﬁcant differences
based on Fisher-tests. b Histone mark enrichment for tagVMRs with best model E, G, G + E and GxE relative to all VMRs. Green colour indicates depletion,
red colour indicates enrichment. Thick black lines around the rectangles indicate signiﬁcant enrichment/depletion based on Fisher-tests. c Histone mark
enrichment for all DeepSEA variants in the dataset. Blue bars indicate signiﬁcant enrichment/depletion based on Fisher-tests. d Histone mark enrichment
for all DeepSEA variants involved in models where either G, G + E or GxE is the best model as compared to all tested DeepSEA variants. Green colour
indicates depletion, red colour indicates enrichment. Thick black lines around the rectangles indicate signiﬁcant enrichment/depletion based on Fishertests

bipolar disorder42, major depressive disorder43, schizophrenia44
and the cross-disorder associations including all ﬁve of these
disorders45. Additionally, we included GWAS of inﬂammatory
bowel disease46, type 2 diabetes47 and for BMI48. Nominal signiﬁcant GWAS ﬁndings were enriched for DeepSEA variants and
their LD proxies per se across psychiatric as well as nonpsychiatric diseases (Fig. 7a). However, G, GxE and G + E
DeepSEA variants showed a differential enrichment pattern above
all DeepSEA variants (Fig. 7b), with strongest enrichments of
GxE DeepSEA variants in GWAS of autism spectrum disorder
(p < 2.20 × 10−16, OR = 2.07 above DeepSEA, Fisher-test),
attention-deﬁcit-hyperactivity disorder (p < 2.20 × 10−16, OR =
1.71, Fisher-test) and inﬂammatory bowel disease (p < 2.20 ×
10−16, OR = 1.71, Fisher-test) and G + E DeepSEA variants in

GWAS for attention-deﬁcit-hyperactivity disorder (p = 9.54 ×
10−36, OR = 1.23, Fisher-test) and inﬂammatory bowel disease
(p = 1.85 × 10−52, OR = 1.30, Fisher-test). While SNPs with
strong main meQTL effects such as those within G and G + E
models have been reported to be enriched in GWAS for common
disease, we now also show this for SNPs within GxE models that
often have non-signiﬁcant main G effects.
Discussion
We evaluated the effects of prenatal environmental factors and
genotype on DNA methylation at VMRs identiﬁed in neonatal
blood samples. We found that most variable methylation sites
were best explained by either genotype and prenatal environment
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Fig. 5 VMR analysis in PREDO I and replication datasets. Percentage of models (G, E, GxE or G + E) with the lowest AIC explaining variable DNA
methylation in PREDO I (450 K), DCHS I (450 K), PREDO II (EPIC), UCI (EPIC) and DCHS II (EPIC)

Table 2 VMRs and best models across cohorts
Cohort
Sample-size
Methylation array
# VMRs
Proportion: best model E (%)
Best model G (%)
Best model G + E (%)
Best model GxE (%)

PREDO I
817
Illumina 450 K
3972
2.0
30.0
30.0
38.0

PREDO II
146
Illumina EPIC
8547
<1
15.0
29.0
56.0

interactions (GxE) or additive effects (G + E) of these factors,
followed by main genotype effects. This pattern was replicated in
independent cohorts and underscores the need to consider genotype in the study of environmental effects on DNA methylation.
In fact, VMRs best explained by G, G + E or GxE and their
associated functional genetic variants were located in distinct
genomic regions, suggesting that different combinatorial effects of
G and E may impact VMRs with distinct downstream regulatory
effects and thus possibly context-dependent impact on cellular
function. We also observed that functional variants with best
models G, G + E or GxE, all showed signiﬁcant enrichment
within GWAS signals for complex disorders beyond the enrichment of the functional variants themselves. While this was
expected for G and G + E models based on results from previous
studies21,23,24,26, it was surprising for GxE SNPs, as these often do
not have highly signiﬁcant main genetic effects. Their speciﬁc
enrichment in GWAS for common disorders supports the
importance of these genetic variants that moderate environmental
impact both at the level of DNA methylation but also, potentially,
for disease risk.
The fact that GxE and G + E best explained the majority of
VMRs (see Fig. 5) and that GxE models were selected by a larger
margin than the other models (see Fig. 2c) was consistently found
across all tested cohorts. These ﬁndings are in line with a previous
report by Teh et al.29 who performed a similar analysis based on
AIC in umbilical cord tissue. Differences to the ﬁndings by Teh
et al. are discussed in the Supplemental Discussion. Using data
from four different cohorts, we not only saw comparable proportions of VMRs best explained by the different models, but also
saw in the VMRs common across cohorts that speciﬁc VMRs had
consistent best models (see Fig. 6). This is in line with the fact
8

DCHS I
107
Illumina 450 K
6072
<1
15.8
29.8
54.3

DCHS II
151
Illumina EPIC
10,005
<1
11.5
32.1
56.3

UCI
121
Illumina EPIC
9525
4.1
12.8
24.1
59.0

that VMRs best explained by G, GxE or G + E show functional
differences and may differentially impact gene regulation.
In addition to consistent ﬁndings using AIC-based approaches,
we also observed some indication for validation of individual GxE
and G + E combinations on selected VMRs using p-value based
criteria, with a small number of speciﬁc G + E and GxE effects on
VMRs replicating between the PREDO I and the MoBa cohort.
The low number of speciﬁc replications could be due to lack of
overall power as well as larger differences in prenatal factors
between these two cohorts (see Table 1). As shown in Supplementary Fig. 4B, which speciﬁc G and E combinations best
explain VMRs is also dependent on the speciﬁc prenatal factors.
Larger and more homogenous cohorts regarding exposures will
be needed for such analyses to be more conclusive.
While E alone was rarely the best model, it should be pointed
out that main environmental effects on DNA methylation were
observed (see Supplementary Data 3), and consistent with previous large meta-analyses such as in the case of maternal smoking
(see Supplementary Note 7). Within the MoBa cohort, the cohort
with the largest proportion of maternal smoking, 10% of all
tagCpGs were best explained by maternal smoking alone. However, in all other cohorts, where smoking was less prevalent, the
inclusion of genotypic effects in addition to maternal smoking
explained more of the variance. This supports that while main E
effects on the newborn methylome are present, genotype is an
important factor that, in combination with E, may explain even
more of the variance in DNA methylation.
VMRs best explained by either E, G, G + E or GxE and their
associated functional SNPs were enriched for distinct genomics
locations and chromatin states (see Fig. 4), suggesting that VMRs
moderated by different combinations of G and E may in fact have
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distinct functional roles in gene regulation. Overall, VMRs best
explained by GxE were consistently enriched for regions annotated to the OpenSea regions with lower CpG density and located
farthest from CpG Islands49. Open Sea regions have been
reported to be enriched for environmentally-associated CpGs
with for example exposure to childhood trauma50 and may harbour more long-range enhancers.
In addition to their position relative to CpG islands and their
CpG content, G, GxE and G + E VMRs and their associated
functional SNPs also showed distinct enrichments for chromatin
marks. Compared to 450 K VMRs in general, VMRs with GxE as
the best models were relatively depleted in regions surrounding
the TSS, while VMRs with G + E were relatively enriched in these
regions (see Fig. 4), suggesting that GxE VMRs are located at
more distance from the TSS than G + E VMRs. To better map the
potential functional variants in these models and to compare
methylation-associated SNPs from a regulatory perspective, we
used DeepSEA38, a machine learning algorithm that predicts SNP
functionality from the sequence context based on sequencing data
for different regulatory elements in different cell lines using
ENCODE data39. We identiﬁed the SNPs with putatively functional consequences on regulatory marks by DeepSEA and
compared putative regulatory effects of G, G + E and GxE hits.
Relative to the imputed non-DeepSEA SNPs contained in our
dataset, these predicted functional DeepSEA SNPs were enriched
for TSS and enhancer regions and depleted for quiescent regions,
supporting their relevance in regulatory processes (see Fig. 4).
Compared to DeepSEA SNPs overall, DeepSEA SNPs within the
three different best models also showed distinct enrichment or
depletion patterns. Similar to GxE VMRs, likely functional GxE
SNPs also showed a relative depletion in TSS regions while G + E
SNPs showed enrichment in genic enhancers. Overall, both the
VMRs as well as the associated functional SNPs appear to be in
distinct regulatory regions, depending on their best model. In
addition, GxE functional SNP and tagCpGs were located farther
apart than SNP/tagCpG pairs within G or G + E models (see
Supplementary Fig. 5B), supporting a more long-range type of
regulation in GxE interactions on molecular traits as compared to

T2D
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MDD

IBD

BP

CrossDisorder

BMI

Fig. 6 Consistency of best models across cohorts. Percentage of consistent
best models in overlapping tag CpGs of PREDO I (450 K), DCHS I (450 K),
PREDO II (EPIC), UCI (EPIC) and DCHS II (EPIC). Overlapping VMRs
included signiﬁcantly more CpGs as compared to all VMRs (p < 2.2 × 10−16,
Wilcoxon-test, mean = 4.43)

G
ASD

Overlapping tagCpGs

ADHD

0.00

Fig. 7 Enrichment of DeepSEA variants for GWAS associations.
a Enrichment for nominal signiﬁcant GWAS associations for all tested
DeepSEA variants and their LD proxies for GWAS for ADHD (attentiondeﬁcit hyperactivity disorder), ASD (autism spectrum disorder), BMI (body
mass index), BP (bipolar disorder), CrossDisorder, IBD (inﬂammatory
bowel disease), MDD (major depressive disorder), SCZ (schizophrenia)
and T2D (Type 2 diabetes). The Y-axis denotes the fold enrichment with
regard to non-DeepSEAvariants. Blue bars indicate signiﬁcant enrichment/
depletion based on Fisher-tests. b Enrichment for nominal signiﬁcant
GWAS hits for DeepSEA variants and their LD proxies involved in best
models with G, G + E or GxE as compared to all tested DeepSEA variants.
Green colour indicates depletion, red colour indicates enrichment. Thick
black lines around the rectangles indicate signiﬁcant enrichment/depletion
based on Fisher-tests

all genes; a similar relationship has been reported previously for
GxE with regard to gene expression in C. elegans51,52.
SNPs associated with differences in gene expression but also
DNA methylation have consistently been shown to be enriched
among SNPs associated with common disorders in
GWAS21,24,26,53. The functional genetic variants that were within
G, GxE or G + E models predicting variable DNA methylation
were even enriched in GWAS association results (beyond the
baseline enrichment of DeepSea SNPs per se). The fact that such
enrichment was observed for not only G and G + E SNPs, with
strong main genetic effects, but also for GxE SNPs, with smaller
to sometimes no main genetic effect on DNA methylation
underscores the importance of also including SNPs within GxE
models in the functional annotation of GWAS. A detailed catalogue of meQTLs that are responsive to environmental factors
could support a better pathophysiological understanding of diseases for which risk is shaped by a combination of environment
and genetic factors.
Finally, we want to note the limitations of this study. First, we
restricted our analyses to speciﬁc DNA methylation array contents that are inherently biased as compared to genome-wide
bisulﬁte sequencing, for example. In addition, we restricted our
analysis to VMRs, which also limits the generalisability of the
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ﬁndings, but also has advantages. Ong and Holbrooke54 showed
that this approach increases statistical power. Furthermore,
VMRs are enriched for enhancers and transcription factor
binding sites, overlap with GWAS hits55 and are associated with
gene expression of nearby genes at these sites56. VMRs in this
study presented with intermediate methylation levels which have
been shown to be enriched in regions of regulatory function, like
enhancers, exons and DNase I hypersensitivity sites57. Hence, the
effects of genotypes on DNA methylation levels in VMRs might
be higher as compared to less variable CpG-sites. In addition,
genotypes are measured with much less error as compared to
environmental factors which may also reduce the overall
explained variance in large cohorts.
Second, it has been reported that different cell types display
different patterns of DNA methylation55. Therefore, the most
variable CpG-sites may also include those that reﬂect differences
in cord blood cell type proportions. To address this issue, all
analyses were corrected for estimated cell proportions to the best
of our current availability, so that differences in cell type proportion likely do not account for all of the observed effects.
However, only replication in speciﬁc cell types will be able to truly
assess the proportion of VMRs inﬂuenced by this.
Third, we used the AIC as main criterion for model ﬁt37 which
is equivalent to a penalised likelihood-function. There are a
variety of other model selection criteria58 and choosing between
these is an ongoing debate which also depends on the underlying
research question. We decided to use the AIC as one of our main
aims was to compare our results with the study of Teh et al.29 in
which this criterion was applied and as this method maybe more
powerful for detecting GxE than for example model selection
criteria based on lowest p-values.
Fourth, all reported interactions are statistical interactions and
limited to a cis window around the CpG-site. Further experiments
are required to assess whether these would also reﬂect biological/
mechanistic interactions. Much larger cohorts will be needed to
assess potential trans effects. Additional inclusion of further
covariates such as maternal smoking or maternal age may further
modify the effects of speciﬁc Es but is beyond the scope of this
manuscript.
Fifth, as summarised in Table 1, results presented are based on
cohorts which differ in ethnicity, assessed phenotypes, methylation and SNP arrays, processing pipelines and sample sizes. While
all these factors may contribute to differences in the proportions
of models across the cohorts, it also suggests that our ﬁndings are
quite robust to these methodological issues.
Finally, our analyses are restricted to DNA methylation in
neonatal blood and to pregnancy environments. Whether similar
conclusions can be drawn for methylation levels assessed at a later
developmental stage needs to be investigated.
We tested whether genotype, a combination of different prenatal environmental factors and the additive or the multiplicative
interactive effects of both mainly inﬂuence VMRs in the newborn’s epigenome. Our results show that G in combination with E
are the best predictors of variance in DNA methylation. This
highlights the importance of including both individual genetic
differences as well as environmental phenotypes into epigenetic
studies and also the importance of improving our ability to
identify environmental associations. Our data also support the
disease relevance of variants predicting DNA methylation together with the environment beyond main meQTL effects, and the
view that there are functional differences of additive and interactive effects of genes and environment on DNA methylation.
Improved understanding of these functional differences may also
yield novel insights into pathophysiological mechanisms of
common non-communicable diseases, as risk for all of these
disorders is driven by both genetic and environmental factors.
10

Methods
The PREDO cohort. The Prediction and Prevention of Preeclampsia and Intrauterine Growth Restriction (PREDO) Study is a longitudinal multicenter pregnancy
cohort study of Finnish women and their singleton children born alive between
2006 and 2010 30. We recruited 1,079 pregnant women, of whom 969 had one or
more and 110 had none of the known clinical risk factors for preeclampsia and
intrauterine growth restriction. The recruitment took place when these women
attended the ﬁrst ultrasound screening at 12 + 0–13 + 6 weeks + days of gestation
in one of the ten hospital maternity clinics participating in the study. The cohort
proﬁle30 contains details of the study design and inclusion criteria.
Ethics. The study protocol was approved by the Ethical Committees of the Helsinki
and Uusimaa Hospital District and by the participating hospitals. A written
informed consent was obtained from all women.
Maternal characteristics. We tested 10 different maternal environments:
Depressive symptoms. Starting from 12 + 0–13 + 6 gestational weeks + days
pregnant women ﬁlled in the 20 item Center for Epidemiological Studies
Depression Scale (CES-D)59 for depressive symptoms in the past 7 days. They ﬁlled
in the CES-D scale biweekly until 38 + 0–39 + 6 weeks + days of gestation or
delivery. We used the mean-value across all the CES-D measurements.
Symptoms of anxiety. At 12 + 0–13 + 6 weeks + days of gestation, women ﬁlled
in the 20 item Spielberger’s State Trait Anxiety Inventory (STAI)60 for anxiety
symptoms in the past 7 days. They ﬁlled in the STAI scale biweekly until 38 +
0–39 + 6 weeks + days of gestation or delivery. We used the mean-value across all
these measurements.
Betamethasone. Antenatal betamethasone treatment (yes/no) was derived from
the hospital records and the Finnish Medical Birth Register (MBR).
Delivery method. Mode of delivery (vaginal delivery vs. caesarean section) was
derived from patient records and MBR.
Parity. Parity (number of previous pregnancies leading to childbirth) at the start of
present pregnancy was derived from the hospital records and the MBR.
Maternal age. Maternal age at delivery (years) was derived from the hospital
records and the MBR.
Pre-pregnancy BMI. Maternal pre-pregnancy BMI (kg/m2), calculated from
measurements weight and height veriﬁed at the ﬁrst antenatal clinic visit at 8 + 4
(SD 1 + 3) gestational week was derived from the hospital records and the MBR.
Hypertension. Hypertension was deﬁned as any hypertensive disorder including
gestational hypertension, chronic hypertension and preeclampsia against normotension. Gestational hypertension was deﬁned as systolic/diastolic blood pressure
≥140/90 mm Hg on ≥2 occasions at least 4 h apart in a woman who was normotensive before 20th week of gestation. Preeclampsia was deﬁned as systolic/diastolic
blood pressure ≥140/90 mm Hg on ≥2 occasions at least 4 h apart after 20th week
of gestation and proteinuria ≥300 mg/24 h. Chronic hypertension was deﬁned as
systolic/diastolic blood pressure ≥140/90 mm Hg on ≥2 occasions at least 4 h apart
before 20th gestational week or medication for hypertension before 20 weeks of
gestation.
Gestational diabetes and oral glucose tolerance test. Gestational diabetes was
deﬁned as fasting, 1 h or 2 h plasma glucose during a 75 g oral glucose tolerance test
≥5.1, ≥10.0 and/or ≥8.5 mmol/L, respectively, that emerged or was ﬁrst identiﬁed
during pregnancy. We took the area under the curve from the three measurements
as a single measure for the oral glucose tolerance test (OGTT) itself.
Genotyping and imputation. Genotyping was performed on Illumina Human
Omni Express Exome Arrays containing 964,193 SNPs. Only markers with a call
rate of at least 98%, a minor allele frequency of at least 1% and a p-value for
deviation from Hardy-Weinberg-Equilibrium >1.0 × 10−06 were kept in the analysis. After QC, 587,290 SNPs were available.
In total, 996 cord blood samples were genotyped. Samples with a call rate below
98% (n = 11) were removed.
Any pair of samples with IBD estimates >0.125 was checked for relatedness. As
we corrected for admixture in our analyses using MDS-components (see
Supplementary Fig. 10), these samples were kept except for one pair which could
not be resolved. From this pair we excluded one sample from further analysis.
Individuals showing discrepancies between phenotypic and genotypic sex (n = 1)
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were removed. We also checked for heterozygosity outliers but found none. Nine
hundred and eighty-three participants were available in the ﬁnal dataset.
Before imputation, AT and CG SNPs were removed. Imputation was performed
using shapeit2 (http://mathgen.stats.ox.ac.uk./genetics_software/shapeit/shapeit.
html) and impute2 (https://mathgen.stats.ox.ac.uk/impute/impute_v2.html).
Chromosomal and base pair positions were updated to the 1000 Genomes Phase 3
reference set, allele strands were ﬂipped where necessary.
After imputation, we reran quality control, ﬁltering out SNPs with an info
score <0.8, a minor allele frequency below 1% and a deviation from HWE with a
p-value <1.0 × 10 -06.
This resulted in a dataset of 9,402,991 SNPs. After conversion into best guessed
genotypes using a probability threshold of 90%, we performed another round of
QC (using SNP-call rate of least 98%, a MAF of at least 1% and a p-value threshold
for HWE of 1.0 × 10−06), after which 7,314,737 SNPs remained for the analysis.
For the evaluation of which model best explained the methylation sites, we
pruned the dataset using a threshold of r2 of 0.2 and a window-size of 50 SNPs with
an overlap of 5 SNPs. The ﬁnal, pruned dataset contained 788,156 SNPs. 36,241 of
these variants were DeepSea variants (see Methods below).
DNA methylation. Cord blood samples were run on Illumina 450k Methylation
arrays. The quality control pipeline was set up using the R-package minﬁ61 (https://
www.r-project.org). Three samples were excluded as they were outliers in the
median intensities. Furthermore, 20 samples showed discordance between phenotypic sex and estimated sex and were excluded. Nine samples were contaminated
with maternal DNA according to the method suggested by Morin et al.62 and were
also removed.
Methylation beta-values were normalised using the funnorm function63. After
normalisation, two batches, i.e., slide and well, were signiﬁcantly associated and
were removed iteratively using the Combat function64 in the sva package65.
We excluded any probes on chromosome X or Y, probes containing SNPs and
cross-hybridising probes according to Chen et al.53 and Price et al.66 Furthermore,
any CpGs with a detection p-value >0.01 in at least 25% of the samples were
excluded.
The ﬁnal dataset contained 428,619 CpGs and 822 participants. For 817 of
these, also genotypes were available.
An additional 161 cord blood samples were run on Illumina EPIC Methylation
arrays.
Three samples were excluded as they were outliers in the median intensities.
Three samples showed discordance between phenotypic sex and estimated sex and
were excluded. Three samples were contaminated with maternal DNA and were
also removed62.
Methylation beta-values were normalised using the funnorm function63 in the
R–package minﬁ61. Three samples showed density artefacts after normalisation and
were removed from further analysis. We excluded any probes on chromosome X or
Y, probes containing SNPs and cross-hybridising probes according to Chen et al.53,
Price et al.66 and McCartney et al.67. Furthermore, any CpGs with a detection pvalue >0.01 in at least 25% of the samples were excluded. The ﬁnal dataset contains
812,987 CpGs and 149 samples. After normalisation no signiﬁcant batches were
identiﬁed. For 146 of these samples, genotypic data was also available.
Cord blood cell counts were estimated for seven cell types (nucleated red blood
cells, granulocytes, monocytes, natural killer cells, B cells, CD4(+)T cells, and CD8
(+)T cells) using the method of Bakulski et al.68 which is incorporated in the Rpackage minﬁ61.
Identiﬁcation of VMRs (variable methylated regions). The VMR approach was
described by Ong and Holbrook54. We chose all 42,862 CpGs with a MAD score
greater than the 90th percentile. For each CpG-site, the MAD (median absolute
deviation) is deﬁned as the median of the absolute deviations from each individual’s methylation beta-value at this CpG-site to the CpG’s median. A candidate
VMR region was deﬁned as at least two spatially contiguous probes which were at
most 1 kb apart of each other. This resulted in 3982 VMRs in the 450 K samples
and in 8547 VMRs in the EPIC sample. The CpG with the highest MAD scores was
chosen as representative of the whole VMR in the statistical analysis.
The Drakenstein cohort. Details on this cohort and the assessed phenotypes can
be found in refs. 34,35. The birth cohort design recruits pregnant women attending
one of two primary health care clinics in the Drakenstein sub-district of the Cape
Winelands, Western Cape, South Africa – Mbekweni (serving a black African
population) and TC Newman (serving a mixed ancestry population). Consenting
mothers were enroled during pregnancy, and mother–child dyads are followed
longitudinally until children reach at least 5 years of age. Mothers are asked to
request that the father of the index pregnancy attend a single antenatal study visit
where possible. Follow-up visits for mother–child dyads take place at the two
primary health care clinics and at Paarl Hospital.
Pregnant women were eligible to participate if they were 18 years or older, were
accessing one of the two primary health care clinics for antenatal care, had no
intention to move out of the district within the following year, and provided signed
written informed consent. Participants were enroled between 20 and 28 weeks’
gestation, upon presenting for antenatal care visit. In addition, consenting fathers
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of the index pregnancy when available were enroled in the study and attended a
single antenatal study visit.
Ethics. The study was approved by the Faculty of Health Sciences, Human
Research Ethics Committee, University of Cape Town (401/2009), by Stellenbosch
University (N12/02/0002), and by the Western Cape Provincial Health Research
committee (2011RP45). All participants provided written informed consent.
Maternal characteristics. After providing consent, participants were asked to
complete a battery of self-report and clinician-administered measures at a number
of antenatal and postnatal study visits. All assessed phenotypes are described in
detail in ref. 34. Here, we give a short outline on the phenotypes which were used in
our analysis. Maternal parity was obtained from the antenatal record; maternal age
was from the date of birth as recorded on the mothers’ national identity document.
The mode of delivery was ascertained by direct observation of the birth by a
member of the study team as all births occurred at Paarl hospital. The SRQ-2069 is
a WHO-endorsed measure of psychological distress consisting of 20 items which
assess non-psychotic symptoms, including symptoms of depressive and anxiety
disorders. Each item is scored according to whether the participant responds in the
afﬁrmative (scored as 1) or negative (scored as 0) to the presence of a symptom.
Individual items are summed to generate a total score. The Beck Depression
Inventory (BDI-II) is a widely-used and reliable measure of depressive symptoms70. The BDI-II comprises 21 items, each of which assesses the severity of a
symptom of major depression. Each item is assessed on a severity scale ranging
from 0 (absence of symptoms) to 3 (severe, often with functional impairment). A
total score is then obtained by summing individual item responses, with a higher
score indicative of more severe depressive symptoms.
Smoking was assessed using The Alcohol, Smoking and Substance Involvement
Screening Test (ASSIST)71, a tool that was developed by the WHO to detect and
manage substance use among people attending primary health care services. The
tool assesses substance use and substance-related risk across 10 categories (tobacco,
alcohol, cannabis, cocaine, amphetamine-type stimulants, inhalants, sedatives/
sleeping pills, hallucinogens, opioids and other substances), as well as enquiring
about a history of intravenous drug use. Total scores are obtained for each
substance by summing individual item responses, with a higher score indicative of
greater risk for substance-related health problems.
Hypertension was assessed by blood pressure measured antenatally.
Genotyping and Imputation. Genotyping in DCHS was performed using the
Illumina PsychArray for those samples with 450k data, or the Illumina GSA for
those samples with EPIC DNA methylation data (Illumina, San Diego, USA). For
both array types, QC and imputation was the same; ﬁrst, raw data was imported
into Genome Studio and exported into R for QC. SNPs were ﬁltered out if they had
a tenth percentile GC score below 0.2 or an average GC score below 0.1, for a total
of 140 SNPs removed. Phasing was performed using shapeit, and imputation was
performed using impute2 with 1000 Genomes Phase 1 reference data. After
imputation, we used qctool to ﬁlter out SNPs with an info score <0.8 or out of
Hardy–Weinberg equilibrium. All SNPs with MAF <1% were removed.
As after imputation, only 5286 DeepSEA variants were available for those
samples genotyped on the PsychArray and only 4049 for those samples genotyped
on the GSAchip, we performed LD-pruning based on a threshold of r2 of 0.2 and a
window-size of 50 SNPs with an overlap of 5 SNPs. This resulted in 162,292 SNPs
(PsychArray) and 176,553 SNPs (GSAchip).
DNA methylation. We performed basic quality control on data generated by either
the 450k or EPIC arrays using Illumina’s Genome Studio software for background
subtraction and colour correction. Data was ﬁltered to remove CpGs with high
detection p values, those on the X or Y chromosome, or with previously identiﬁed
poor performance. 450k data was normalised using SWAN and EPIC data using
BMIQ, and both used ComBat to correct for chip (both), and row (450k only).
Details for DNA methylation measurements and quality control have been published62. The ﬁnal analysis was performed with 107 samples with methylation levels
from the 450k array and 151 with methylation levels assessed on the EPIC array
and available genotypes. Neonatal blood cell counts were estimated for seven cell
types: nucleated red blood cells, granulocytes, monocytes, natural killer cells, B
cells, CD4(+)T cells, and CD8(+)T cells68.
VMRs. We identiﬁed 6072 candidate VMRs in DCHS I and 10,005 candidate
VMRs in DCHS II.
The UCI cohort. Mothers and children were part of an ongoing, longitudinal study,
conducted at the University of California, Irvine (UCI), for which mothers were
recruited during the ﬁrst trimester of pregnancy31–33. All women had singleton,
intrauterine pregnancies. Women were not eligible for study participation if they
met the following criteria: corticosteroids, or illicit drugs during pregnancy (veriﬁed by urinary cotinine and drug toxicology). Exclusion criteria for the newborn
were preterm birth (i.e., less than 34 weeks of gestational age at birth), as well as
any congenital, genetic, or neurologic disorders at birth.
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Ethics. The UCI institutional review board approved all study procedures and all
participants provided written informed consent.
Maternal characteristics. Maternal sociodemographic characteristics (age, parity)
were obtained via a standardised structured interview at the ﬁrst pregnancy visit.
Maternal pre-pregnancy BMI (weight kg/height m2) was computed based on prepregnancy weight abstracted from the medical record, and maternal height was
measured at the research laboratory during the ﬁrst pregnancy visit. Obstetric risk
conditions during pregnancy, including presence of gestational diabetes and
hypertension, and delivery mode were abstracted from the medical record. At each
pregnancy visit the Center for Epidemiological Studies Depression Scale59 and the
State scale from the State–Trait Anxiety Inventory60 were administered. For
individuals with <3 missing items on any scale at any time point, the mean
responses for that scale were calculated and then multiplied by the total number of
items in the respective scale, to generate total scale scores that are comparable to
those generated from participants without any missing data. We used the average
depression and anxiety score throughout pregnancy in the calculations. Maternal
smoking during pregnancy was determined by maternal self-report and veriﬁed by
measurement of urinary cotinine concentration. Urinary cotinine was assayed in
maternal samples collected at each trimester using the Nicotine/COT(Cotinine)/
Tobacco Drug Test Urine Cassette (http://www.meditests.com/nicuintescas.html),
which involves transferring 4 drops of room temperature urine into the well of the
cassette, and employs a cutoff for COT presence of 200 ng/ml. Endorsement of
smoking or detection of urinary COT in any trimester was coded as 1, and absence
of evidence for smoking in any trimester coded as 0.
Genotyping. Genomic DNA was extracted from heel prick blood samples and used
for all genomic analysis. Genotyping was performed on Illumina Human Omni
Express (24 v1.1) Arrays containing 713,014 SNPs. All samples had a high call rate
(above 97%). SNPs with a minor allele frequency >5% and a p-value for deviation
from Hardy-Weinberg-Equilibrium >1.0 × 10−25 were retained for analysis. After
QC, 602,807 SNPs were available.
Imputation. Before imputation, chromosomal and base pair positions were
updated to the Haplotype Reference Consortium (r1.1) reference set, allele strands
were ﬂipped where necessary. Phasing was performed using EAGLE2 (https://data.
broadinstitute.org/alkesgroup/Eagle/) and imputation was performed using PBWT
(https://github.com/VertebrateResequencing/pbwt). Imputed SNPs with an info
score <0.8, duplicates and ambiguous SNPs were removed resulting in 21,341,980
SNPs. All SNPs with MAF <0.01 were removed. Of the remaining SNPs, 19,530
were DeepSEA variants.
DNA methylation. DNAm analysis using the Inﬁnium Illumina MethylationEPIC
BeadChip (Illumina, Inc., San Diego, CA) was performed according to the manufacturer´s guidelines in using genomic DNA derived from neonatal heel prick
samples. Quality Control carried out in minﬁ61. No outliers were detected in the
median intensities of methylated and unmethylated channels. All samples had a
high call rate of at least 95% and their predicted sex was the same as the phenotypic
sex. We removed CpGs with a high detection value (p < 0.0001), probes missing >3
beads in >5% of the cohort, in addition to non-speciﬁc/cross-hybridising and SNP
probes66,67. Methylation beta-values were normalised using functional normalisation (funnorm)63. We also iteratively adjusted the data for relevant technical
factors, i.e., array row, experimental batch and sample plate, using Combat64. The
ﬁnal dataset contained 768,910 CpGs. Neonatal blood cell counts were estimated
for seven cell types: nucleated red blood cells, granulocytes, monocytes, natural
killer cells, B cells, CD4(+)T cells, and CD8(+)T cells68. The ﬁnal dataset contained 121 samples with available genotypes and methylation values.
VMRs. Applying the same procedure as for PREDO I and PREDO II, we identiﬁed
9525 candidate VMRs in the ICU cohort.
The MoBa cohort. Participants represent two subsets of mother-offspring pairs
from the national Norwegian Mother and Child Cohort Study (MoBa)72. MoBa is a
prospective population-based pregnancy cohort study conducted by the Norwegian
Institute of Public Health. The years of birth for MoBa participants ranged from
1999 to 2009. MoBa mothers provided written informed consent. Each subset is
referred to here as MoBa1 and MoBa2. MoBa1 is a subset of a larger study within
MoBa that included a cohort random sample and cases of asthma at age 3 years73.
We previously reported an association between maternal smoking during pregnancy and differential DNA methylation in MoBa1 newborns74. We subsequently
measured DNA methylation in additional newborns (MoBa2) in the same
laboratory (Illumina, San Diego, CA)11. MoBa2 included cohort random sample
plus cases of asthma at age 7 years and non-asthmatic controls. Years of birth were
2002–2004 for children in MoBa1, 2000–2005 for MoBa2.
Ethics. The establishment and data collection in MoBa obtained a license from the
Norwegian Data Inspectorate and approval from The Regional Committee for
Medical Research Ethics. Both studies were approved by the Regional Committee
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for Ethics in Medical Research, Norway. In addition, MoBa1 and MoBa2 were
approved by the Institutional Review Board of the National Institute of Environmental Health Sciences, USA.
Maternal characteristics. To replicate speciﬁc GxE and G + E from PREDO I, we
focused on those characteristics which were available in both cohorts: maternal age,
pre-pregnancy BMI and hypertension.
Within MoBa, the questionnaires at weeks 17 and 30 include general
background information as well as details on previous and present health problems
and exposures. The birth record from the Medical Birth Registry of Norway75
which includes maternal health during pregnancy as well as procedures around
birth and pregnancy outcomes, is integrated in the MoBa database.
Genotyping and imputation. DNA was extracted from the MoBa biobank and
genotyped on the Illumina HumanExomeCore platform. The genotypes were called
with GenomeStudio software. Phasing and imputation were done using shapeit2
(https://mathgen.stats.ox.ac.uk./genetics_software/shapeit/shapeit.html) and
impute2 (https://mathgen.stats.ox.ac.uk/impute/impute_v2.html) with the thousand genomes phase 3 reference panel for the European population. Variants with
a imputation score of <0.8 and with a minor allele frequency below 1% were
ﬁltered out.
DNA methylation. Details of the DNA methylation measurements and quality
control for the MoBa1 participants were previously described36 and the same
protocol was implemented for the MoBa2 participants. Brieﬂy, at birth, umbilical
cord blood samples were collected and frozen at birth at −80 °C. All biological
material was obtained from the Biobank of the MoBa study36. Bisulﬁte conversion
was performed using the EZ-96 DNA Methylation kit (Zymo Research Corporation, Irvine, CA) and DNA methylation was measured at 485,577 CpGs in cord
blood using Illumina’s Inﬁnium HumanMethylation450 BeadChip76. Raw intensity
(.idat) ﬁles were handled in R using the minﬁ package to calculate the methylation
level at each CpG as the beta-value (β = intensity of the methylated allele (M)/
(intensity of the unmethylated allele (U)+ intensity of the methylated allele (M) +
100)) and the data was exported for quality control and processing. Control probes
(N = 65) and probes on X (N = 11 230) and Y (N = 416) chromosomes were
excluded in both datasets. Remaining CpGs missing >10% of methylation data
were also removed (N = 20 in MoBa1, none in MoBa2). Samples indicated by
Illumina to have failed or have an average detection p value across all probes <0.05
(N = 49 MoBa1, N = 35 MoBa2) and samples with gender mismatch (N = 13
MoBa1, N = 8 MoBa2) were also removed. For MoBa1 and MoBa2, we accounted
for the two different probe designs by applying the intra-array normalisation
strategy Beta Mixture Quantile dilation (BMIQ)77. The Empirical Bayes method via
ComBat was applied separately in MoBa1 and MoBa2 for batch correction using
the sva package in R65. After quality control exclusions, the sample sizes were 1068
for MoBa1 and 685 for MoBa2.
After QC, the total number of samples was 1732, with 1592 overlapping with
the methylation samples. Speciﬁc G + E and GxE associations were calculated in
the combined dataset of MoBa1 and MoBa2, while VMR analysis was conducted in
MoBa1 only.
Regression analysis. Linear regression analysis was conducted using the lm
function in R 3.3.1 (https://www.r-project.org). We included the child’s sex,
gestational age, seven estimated cell counts as well as the ﬁrst two (PREDO I and
PREDO II), ﬁrst three (UCI) and ﬁrst ﬁve (DCHS I and II) principal components
of the MDS analysis on the genotypes in the model. The corresponding plot of the
ﬁrst ten MDS-components in PREDO is depicted in Figure S4. SNP genotypes were
recoded into a count of 0, 1 or 2 representing the number of minor allele copies.
For each VMR site, we tested SNPs located in a 1MB window up- and downstream
of the speciﬁc site. In PREDO and UCI, we restricted the analysis to DeepSEA
variants while we used the pruned SNP-set in DCHS.
For each VMR, we tested four models:
Methylation at tagCpG ~ covariates + environment
Methylation at tagCpG ~ covariates + SNP
Methylation at tagCpG ~ covariates + SNP + environment
Methylation
at
tagCpG
~
covariates + SNP + environment +
SNP×environment
In model (1) we included all ten different environments, in model (2) all
DeepSEA cis SNPs and in models (3) and (4) all possible environment-cis-SNP
combinations. Please also see Fig. 1.
For each model, the AIC, Akaike’s information criterion37 was calculated and
the model with the lowest AIC was chosen as the best model. The AIC was
obtained using the AIC function in R 3.3.1 (https://www.r-project.org).
P-values were obtained from the summary function and adjusted for the
number of tested Es (E model), of tested cis SNPs (G model) or of tested cis SNPenvironment combinations (G + E/GxE model) using Bonferroni-correction.
Afterwards, we used FDR to correct for all tested tagCpGs (all models) using p.
adjust in R.
(1)
(2)
(3)
(4)
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Enrichment analyses. With regard to enrichment for VMRs, CpG-site within
VMRs were compared to all other CpG-sites on the 450 K array located in nonVMR-regions. With regard to enrichment for VMRs best explained by G, G + E or
GxE, tagCpGs best explained by the speciﬁc model were compared to tagCpGs best
explained by any of the other models. For enrichment tests for DeepSEA SNPs,
non-DeepSEA SNPs present in our dataset were used as comparison group.
Enrichment tests were performed based on a hyper-geometric test, i.e. a Fisher-test.
The signiﬁcance levels was set at p < 0.05.
With regard to enrichment for GWAS hits, DeepSEA variants were matched to
GWAs variants based on chromosome and position (hg19). To check for
enrichment for nominal signiﬁcant GWAS hits, the full summary statistics were
derived from the respective publication.
Histone ChiP-seq peaks from Roadmap Epigenomics project for blood and
embryonic stem cells were downloaded from http://egg2.wustl.edu/roadmap/data/
byFileType/peaks/consolidated/broadPeak/.
The pre-processed consolidated broad peaks from the uniform processing
pipeline of the Roadmap project were used.

7.

8.
9.

10.
11.

12.

13.
Genomic annotation mapping. CpG sites were mapped to the genome location
according to Illumina’s annotation using the R-package minﬁ.
14.
DeepSEA analysis. Pretrained DeepSEA model was downloaded from:
http://deepsea.princeton.edu/media/code/deepsea.v0.94.tar.gz and variant ﬁles
in VCF format are used for producing e-values. VCF ﬁles were ﬁrst split into
smaller ﬁles each containing one million variants and the model was run using the
command line on a server with a NVIDIA Titan X GPU card.
We reran our models using only DeepSEA variants which had been identiﬁed
by the algorithm of Zhou and Troyanskaya38. This method predicts functionality of
a SNP based on the DNA-sequence. We included all 212,210 variants with a
functional signiﬁcance e-value below 5 × 10−05. The e-values represent the
signiﬁcance of the regulatory impact of given variants compared to one million
random variants.
Random-effects meta-analysis. GxE and G + E result for PREDO and for MoBa
were meta-analysed using a random-effects model in the R-package rmeta.
Replication was deﬁned as DeepSEA-tagCpG-environment combinations showing
the same effect direction in both cohorts, presenting with smaller p-values as for
PREDO alone and with a FDR-corrected p-value (across all combinations tested in
the meta-analysis) below 0.05.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
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Data availability
Due to ethical issues and consent the datasets analysed during the current study are not
publicly available. However, an interested researcher can obtain a de-identiﬁed dataset
after approval from the PREDO Study Board. Data requests may be subject to further
review by the national register authority and by the ethical committees. Data can be
obtained upon reasonable request from the PREDO Study Board (predo.study@helsinki.
ﬁ) or individual researchers. The summary statistics of the best models for PREDO I are
accessible at: https:/doi.org/10.6084/m9.ﬁgshare.8074964.
For access to the UCI cohort, please contact claudia.buss@charite.de, for access to DCHS
please contact Heather.Zar@uct.ac.za, for MoBa access please apply for data access at
https:/www.ﬁh.no
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